PExA strengthens IP portfolio with European Patent Office’s “Intention to Grant” for non-invasive analysis of small airway particles during medical ventilation
PExA AB today announced that the European Patent Office (EPO) has issued an “Intention to Grant” for the company’s patent application covering its pioneering solution for non-invasive analysis of small airway particles in ventilated patients.
This patent covers a device and method for analyzing exhaled particles to assess lung function during mechanical ventilation. The solution includes a particle detector measuring key properties of aerosols, such as particle size and quantity, exhaled from the patient’s airways. A programmable data processing unit then interprets this data to detect indications of partial lung collapse and can provide warnings or adjust ventilator settings accordingly, enhancing respiratory monitoring and treatment.
PExA has already obtained patents in the US for adjusting ventilator settings, further strengthening its global intellectual property position. The “Intention to Grant” from the EPO marks a significant milestone in expanding PExA’s patent portfolio, reinforcing its commitment to developing innovative solutions to advance respiratory health and science.
An “Intention to Grant” means that the EPO intends to issue a European patent based on the current application, subject to the completion of final administrative steps.
“We are very excited about this development, as it further strengthens our robust patent portfolio for PExA’s non-invasive technology,” said Tomas Gustafsson, CEO of PExA AB. “By enabling respiratory scientists, researchers, and clinicians to unlock critical molecular insights, our technology is paving the way for earlier diagnoses, better treatments, and improved patient outcomes.”
For further information, please contact:
Tomas Gustafsson, E-post: info@pexa.se
About PExA AB:
PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.